Develops psychedelic therapeutics for mental health disorders, focusing on novel approaches to psychiatric treatments.
Silo Pharma, Inc., a biopharmaceutical company in the developmental stage, is dedicated to pioneering treatments that integrate traditional therapeutics with cutting-edge psychedelic research. The company focuses on addressing unmet medical needs by exploring the potential of psychedelic drugs, such as psilocybin, in treating conditions that have been historically underserved. Silo Pharma aims to acquire and develop intellectual property and technology rights from universities and researchers to advance therapies for rare diseases, with a particular emphasis on depression, mental health disorders, and various neurological conditions.
The company's strategic approach involves leveraging scientific insights into the therapeutic benefits of psychedelics to provide innovative solutions for patients suffering from ailments like depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, Parkinson's disease, and other rare neurological disorders. By bridging the gap between traditional pharmaceuticals and psychedelic research, Silo Pharma aims to pioneer novel treatment modalities that offer new hope to individuals facing challenging health conditions.
Founded in 2010 and headquartered in Englewood Cliffs, New Jersey, Silo Pharma, Inc., formerly known as Uppercut Brands, Inc., underwent a significant transformation in September 2020 to align its focus with the burgeoning field of psychedelic medicine. With a commitment to scientific rigor and therapeutic innovation, the company continues to explore and develop potential breakthroughs that could reshape the landscape of modern healthcare.